PEG-Irinotecan Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This PEG-Irinotecan Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 16 September 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: CONDITIONAL GO
Decision memo
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
The central underwriting question is whether PEG-Irinotecan can convert its Polymer profile and Top I biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | PEG-Irinotecan (query alias: PEG-Irinotecan) |
|---|---|
| Modality / target | Polymer; Top I; TOP1 inhibitors |
| Highest global status | Phase 2 |
| Originator | Jenkem Technology Co., Ltd. |
| Active developers | Jenkem Technology Co., Ltd., JenKem Technology (Tianjin) Co., Ltd. |
The MCP disease footprint includes Metastatic HER2-Negative Breast Carcinoma, Brain metastases, Triple Negative Breast Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07391566 | Phase 1/2 | Not yet recruiting | 99 | Primary endpoint not disclosed in English source |
| NCT07391618 | Phase 2 | Recruiting | 583 | Primary endpoint not disclosed in English source |
| NCT07389265 | Phase 3 | Recruiting | 480 | Primary endpoint not disclosed in English source |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
Etirinotecan Pegol (NKTR‐102) in Patients With Active Brain Metastases From Lung or Breast Cancer
Phase 2; n=27; evaluation: Negative. Reported fields: CNS control rate(12-week) = 17.0 % ; mPFS = 1.4 Month ( 1.3 - 6.9)
A Phase I Dose Escalation Study of Eryaspase in Combination With Modified FOLFIRINOX in Locally Advanced and Metastatic Pancreatic Ductal Adenocarcinoma
Phase 1; n=19; evaluation: Not stated in English source. Reported fields: Incidence of Grade 3 or 4 Adverse Events = 2 Pts ; Incidence of Grade 3 or 4 Adverse Events = 8 Pts
Phase I Study of Proton Therapy in Adjuvant Pancreatic Cancer (Proton-PANC)
Phase 1; n=9; evaluation: Not stated in English source. Reported fields: Incidence of Dose Limiting Toxicites (DLTs) = 0 Dose limiting Toxicities ; Incidence of Dose Limiting Toxicites (DLTs) = 1 Dose limiting Toxicities
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
PEG-Irinotecan addresses Metastatic HER2-Negative Breast Carcinoma, Brain metastases, Triple Negative Breast Cancer. Commercial attractiveness rests on addressable patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Polymer—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The MCP screen returned 4 matched transaction record(s) under the scope “asset-specific.” Partner activity is a market-validation signal, but it does not establish net present value.
5. Transaction precedent and economics
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2019-05-23 | Trovagene Announces Research Collaboration with Nektar Therapeutics to Evaluate Efficacy of the Combination of Onvansertib and ONZEALD™ in Models of Colorectal Cancer | Phase 2 | Financial terms not disclosed |
| 2017-12-22 | Transaction title not available in English source | Phase 3 | Financial terms not disclosed |
| 2016-06-01 | Nektar Licenses European Onzeald Rights to Daiichi Sankyo Europe | Phase 3 | US$20.0M upfront; US$60.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
The milestone feed surfaced a patent-application signal described as “Combination drug therapies for cancer and methods of making and using them”. The milestone feed surfaced a patent-application signal described as “Phosphaplatin Compounds as Immuno-Modulatory Agents and Therapeutic Uses Thereof”. The milestone feed surfaced a patent-application signal described as “Multi-branch, multi-branched ending polyethylene glycol derivative used in click chemistry reactions”.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights.
7. Principal risks and diligence gates
- Clinical differentiation versus current standards and pipeline competitors
- Safety, dose optimization, and long-term tolerability
- Patent scope, territorial rights, manufacturing, and commercial positioning
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
CONDITIONAL GO
Advance with milestone-based economics while efficacy durability, safety differentiation, patent scope, and market positioning are validated.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 2026-09-16. Counts and status fields may change as source records update.
